Would you consider Resmetirom in a patient with metabolic risk factors and persistently elevated transaminases despite lifestyle changes, after a negative workup for other liver diseases, with noninvasive testing suggesting minimal fibrosis (F0–F1)?

Resmetirom is only approved for MASH with F2-3 fibrosis, so it will likely not get approved. If there is evidence of continued hepatic steatosis, and no other competing etiologies, would continue current lifestyle recommendations and repeat fibroscan, ELF or MRE in 1 year. If competing etiologies (e...